The FDA has approved a medication called Stelara (ustekinumab) for treating several chronic inflammatory conditions. It's now available for adults and children (age 6 and older) with moderate to severe plaque psoriasis and active psoriatic arthritis. It's also approved for adults with moderately to severely active Crohn's disease and ulcerative colitis, which are inflammatory bowel diseases. This means Stelara can help with both skin/joint conditions and digestive system conditions.
Stelara works by blocking specific proteins in the body called interleukins that contribute to inflammation. For most conditions, it's given as an injection under the skin. For Crohn's disease and ulcerative colitis, the first dose is given through an IV, followed by regular injections. The timing between doses varies depending on which condition is being treated.
This approval gives healthcare providers another treatment option for patients who may not have responded well to other medications. It's particularly significant because it covers multiple conditions and age groups, making it a versatile addition to available therapies. However, like all medications, Stelara may not work for everyone and can have side effects.
It's important to remember that FDA approval means the drug has been found to be safe and effective for specific uses, but it doesn't mean it's the right choice for every patient. Anyone considering this medication should have a thorough conversation with their doctor about their individual health situation, other treatment options, and what to expect from this therapy.